Ron M. Capone
About Ron M. Capone
Ron M. Capone is a Clinical Account Manager currently at Travere Therapeutics, having previously worked as Regional Transplant Manager at Eurofins Transplant Genomics and Regional Account Manager at Astra Zeneca. He has extensive experience in the pharmaceutical industry, focusing on IgA Nephropathy treatment strategies and sales management.
Work at Travere Therapeutics
Ron M. Capone currently serves as a Clinical Account Manager at Travere Therapeutics, a position he has held since 2023. In this role, he focuses on promoting Sparsentan for the treatment of IgA Nephropathy in regions including Buffalo, Rochester, and the Southern Tier. His responsibilities involve collaborating with healthcare professionals and stakeholders to enhance the understanding and utilization of the treatment.
Previous Experience at Eurofins Transplant Genomics
Before joining Travere Therapeutics, Ron M. Capone worked at Eurofins Transplant Genomics as the Regional Transplant Manager from 2020 to 2023. During his three years in this role, he managed operations in the Northeast United States, focusing on enhancing transplant genomics services and supporting healthcare providers in the region.
Background in Sales and Marketing
Ron M. Capone has a diverse background in sales and marketing within the pharmaceutical industry. He served as Vice President of Sales and Marketing at Vivax Medical Corporation from 2016 to 2019, where he worked in Naugatuck, CT. His experience also includes a role as Regional Account Manager - Managed Care at Astra Zeneca from 2008 to 2015, where he developed strategies to shift treatment paradigms.
Education and Expertise
Ron M. Capone holds a Bachelor's Degree in Business Administration and a Master of Business Administration (M.B.A.) with a concentration in Management, both from Niagara University. His educational background provides a strong foundation for his roles in clinical account management and sales strategy within the healthcare sector.
Achievements in IgA Nephropathy Treatment
Throughout his career, Ron M. Capone has implemented strategies aimed at addressing the progression of IgA Nephropathy. His collaborative efforts with cross-functional partners have optimized the utilization of Sparsentan, contributing to advancements in treatment options for patients suffering from this condition.